Peptide Antagonists of Superantigen Toxins

Overview

Journal Mol Divers

Date 2004 Jun 24

PMID 15209162

Citations 8

Authors

Raymond Kaempfer

Affiliations

Soon will be listed here.

Abstract

Superantigens produced by Staphylococcus aureus and Streptococcus pyogenes are among the most lethal of toxins. Toxins in this large family trigger an excessive cellular immune response leading to toxic shock. Superantigens are secreted by the bacteria as diverse natural mixtures, a complexity that demands development of broad-spectrum countermeasures. We used a rational approach to design short peptides with homology to various domains in a typical superantigen (staphylococcal enterotoxin B) and screened each peptide for its ability to antagonize, in human peripheral blood mononuclear cells, superantigen-mediated induction of the genes encoding T helper 1 cytokines that mediate shock: interleukin-2, interferon-gamma and tumor necrosis factor. A dodecamer peptide proved a potent antagonist against widely different superantigens. This peptide protected mice from killing by superantigens and it was able to rescue mice undergoing toxic shock. The antagonist peptide shows homology to a beta-strand-hinge-alpha-helix domain that is structurally conserved among superantigens, yet currently of unknown function and remote from the binding sites for the known ligands essential for T cell activation, the major histocompatibility complex class II molecule and T cell receptor. The antagonist activity of this peptide thus identifies a novel domain in superantigens that is critical for their toxic action. The antagonist peptide provides a new tool for understanding the mechanism of excessive human immune response activation by superantigens that occurs during toxic shock and for identification of a novel target ligand that may interact with this superantigen domain.

Citing Articles

Role of Superantigens in Various Childhood Inflammatory Diseases.

Noorbakhsh S, Ashouri S, Moradkhani M Infect Disord Drug Targets. 2022; 22(7):76-80.

PMID: 35638540 DOI: 10.2174/1871526522666220530141031.

The rise of staphylococcal super antigens in psoriatic patients: a case-control study.

Atefi N, Noorbakhsh S, Ghavidel Darestani S, Tabatabaei A, Rezaee M Jundishapur J Microbiol. 2014; 7(5):e9912.

PMID: 25147719 PMC: 4138646. DOI: 10.5812/jjm.9912.

Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site.

Xia T, Liang S, Wang H, Hu S, Sun Y, Yu X MAbs. 2014; 6(1):119-29.

PMID: 24423621 PMC: 3929436. DOI: 10.4161/mabs.27106.

CD28: direct and critical receptor for superantigen toxins.

Kaempfer R, Arad G, Levy R, Hillman D, Nasie I, Rotfogel Z Toxins (Basel). 2013; 5(9):1531-42.

PMID: 24022021 PMC: 3798871. DOI: 10.3390/toxins5091531.

Identification of bacterial antigens and super antigens in synovial fluid of patients with arthritis: a cross sectional study.

Noorbakhsh S, Talebi-Taher M, Tabatabaei A Med J Islam Repub Iran. 2013; 27(1):12-6.

PMID: 23483360 PMC: 3592937.

References

Scholl P, Diez A, Mourad W, Parsonnet J, Geha R, Chatila T . Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A. 1989; 86(11):4210-4. PMC: 287420. DOI: 10.1073/pnas.86.11.4210. View

Papageorgiou A, Tranter H, Acharya K . Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol. 1998; 277(1):61-79. DOI: 10.1006/jmbi.1997.1577. View

Swaminathan S, Furey W, Pletcher J, Sax M . Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature. 1992; 359(6398):801-6. DOI: 10.1038/359801a0. View

Arad G, Levy R, Hillman D, KAEMPFER R . Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med. 2000; 6(4):414-21. DOI: 10.1038/74672. View

McCormick J, Yarwood J, Schlievert P . Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol. 2001; 55:77-104. DOI: 10.1146/annurev.micro.55.1.77. View

Arcus V, Proft T, Sigrell J, BAKER H, Fraser J, Baker E . Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. J Mol Biol. 2000; 299(1):157-68. DOI: 10.1006/jmbi.2000.3725. View

Li H, Llera A, Mariuzza R . Structure-function studies of T-cell receptor-superantigen interactions. Immunol Rev. 1998; 163:177-86. DOI: 10.1111/j.1600-065x.1998.tb01196.x. View

Dinges M, Orwin P, Schlievert P . Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000; 13(1):16-34, table of contents. PMC: 88931. DOI: 10.1128/CMR.13.1.16. View

Smoot L, McCormick J, Smoot J, Hoe N, Strickland I, Cole R . Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. Infect Immun. 2002; 70(12):7095-104. PMC: 133074. DOI: 10.1128/IAI.70.12.7095-7104.2002. View

10.

Hoffmann M, Jablonski L, Crum K, Hackett S, Chi Y, Stauffacher C . Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylococcal enterotoxin C1. Infect Immun. 1994; 62(8):3396-407. PMC: 302971. DOI: 10.1128/iai.62.8.3396-3407.1994. View

11.

Choi Y, Herman A, DiGiusto D, Wade T, Marrack P, Kappler J . Residues of the variable region of the T-cell-receptor beta-chain that interact with S. aureus toxin superantigens. Nature. 1990; 346(6283):471-3. DOI: 10.1038/346471a0. View

12.

Choi Y, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J . Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989; 86(22):8941-5. PMC: 298406. DOI: 10.1073/pnas.86.22.8941. View

13.

Janeway Jr C, Yagi J, Conrad P, Katz M, Jones B, Vroegop S . T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev. 1989; 107:61-88. DOI: 10.1111/j.1600-065x.1989.tb00003.x. View

14.

Jardetzky T, Brown J, Gorga J, Stern L, Urban R, Chi Y . Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994; 368(6473):711-8. DOI: 10.1038/368711a0. View

15.

Kotzin B, Leung D, Kappler J, Marrack P . Superantigens and their potential role in human disease. Adv Immunol. 1993; 54:99-166. DOI: 10.1016/s0065-2776(08)60534-9. View

16.

GEREZ L, Arad G, Efrat S, Ketzinel M, KAEMPFER R . Post-transcriptional regulation of human interleukin-2 gene expression at processing of precursor transcripts. J Biol Chem. 1995; 270(33):19569-75. DOI: 10.1074/jbc.270.33.19569. View

17.

GEREZ L, Madar L, Arad G, Sharav T, Reshef A, Ketzinel M . Aberrant regulation of interleukin-2 but not of interferon-gamma gene expression in Down syndrome (trisomy 21). Clin Immunol Immunopathol. 1991; 58(2):251-66. DOI: 10.1016/0090-1229(91)90140-6. View

18.

Proft T, Moffatt S, Berkahn C, Fraser J . Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med. 1999; 189(1):89-102. PMC: 1887688. DOI: 10.1084/jem.189.1.89. View

19.

Sundberg E, Li Y, Mariuzza R . So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Curr Opin Immunol. 2002; 14(1):36-44. DOI: 10.1016/s0952-7915(01)00296-5. View

20.

Bohach G, Fast D, Nelson R, Schlievert P . Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol. 1990; 17(4):251-72. DOI: 10.3109/10408419009105728. View